CA2917484A1 - Improved process for production of monoclonal antibodies - Google Patents

Improved process for production of monoclonal antibodies Download PDF

Info

Publication number
CA2917484A1
CA2917484A1 CA2917484A CA2917484A CA2917484A1 CA 2917484 A1 CA2917484 A1 CA 2917484A1 CA 2917484 A CA2917484 A CA 2917484A CA 2917484 A CA2917484 A CA 2917484A CA 2917484 A1 CA2917484 A1 CA 2917484A1
Authority
CA
Canada
Prior art keywords
temperature
antibody
cell culture
phase
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2917484A
Other languages
English (en)
French (fr)
Inventor
Sanjeev Kumar Mendiratta
Sanjay Bandyopadhyay
Sanjay Patel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zydus Lifesciences Ltd
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of CA2917484A1 publication Critical patent/CA2917484A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2917484A 2013-07-06 2014-07-07 Improved process for production of monoclonal antibodies Abandoned CA2917484A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2285/MUM/2013 2013-07-06
PCT/IN2014/000450 WO2015004679A1 (en) 2013-07-06 2014-07-07 Improved process for production of monoclonal antibodies
IN2285MU2013 IN2013MU02285A (enExample) 2013-07-06 2014-07-07

Publications (1)

Publication Number Publication Date
CA2917484A1 true CA2917484A1 (en) 2015-01-15

Family

ID=51794933

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2917484A Abandoned CA2917484A1 (en) 2013-07-06 2014-07-07 Improved process for production of monoclonal antibodies

Country Status (18)

Country Link
US (1) US20160215319A1 (enExample)
EP (1) EP3019528A1 (enExample)
JP (1) JP2016526385A (enExample)
CN (1) CN105431454A (enExample)
AR (1) AR096839A1 (enExample)
AU (1) AU2014288811B2 (enExample)
BR (1) BR112015032800A2 (enExample)
CA (1) CA2917484A1 (enExample)
EA (1) EA201690171A1 (enExample)
HK (1) HK1218297A1 (enExample)
IL (1) IL243011A0 (enExample)
IN (1) IN2013MU02285A (enExample)
MX (1) MX2016000123A (enExample)
NZ (1) NZ715246A (enExample)
SG (1) SG11201510342VA (enExample)
TW (1) TW201514305A (enExample)
WO (1) WO2015004679A1 (enExample)
ZA (1) ZA201509334B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) * 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2017122157A1 (en) * 2016-01-14 2017-07-20 Dr. Reddy’S Laboratories Limited Cell culture process
US20200087390A1 (en) 2016-12-21 2020-03-19 Amgen Inc. Anti-tnf alpha antibody formulations
JP2020188737A (ja) * 2019-05-23 2020-11-26 東ソー株式会社 抗体依存性細胞傷害活性が向上した抗体の製造方法
KR102682066B1 (ko) * 2021-10-12 2024-07-05 프레스티지바이오로직스 주식회사 항체 집단의 제조 방법
WO2025160161A1 (en) * 2024-01-23 2025-07-31 Amgen Inc. Methods for modulating monoclonal antibody charge variants

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
JP4306813B2 (ja) 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
WO2002076578A1 (en) * 2001-03-27 2002-10-03 Smithkline Beecham Corporation Control of glycoforms in igg
TWI384069B (zh) * 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
WO2011019619A1 (en) * 2009-08-11 2011-02-17 Genentech, Inc. Production of proteins in glutamine-free cell culture media
US9045536B2 (en) * 2009-12-23 2015-06-02 Merck Sharp & Dohme Corp. Cell line 3M
WO2011085095A2 (en) * 2010-01-07 2011-07-14 Dr. Reddy's Laboratories Ltd. Enhanced protein expression
CA2795461C (en) * 2010-04-26 2018-04-24 Novartis Ag Improved cell cultivation process
MY163081A (en) * 2010-12-28 2017-08-15 Chugai Pharmaceutical Co Ltd Animal cell culturing method
KR20150043523A (ko) 2012-09-02 2015-04-22 애브비 인코포레이티드 단백질 불균일성의 제어 방법

Also Published As

Publication number Publication date
HK1218297A1 (zh) 2017-02-10
JP2016526385A (ja) 2016-09-05
AU2014288811B2 (en) 2017-06-08
ZA201509334B (en) 2017-03-29
MX2016000123A (es) 2016-07-14
EA201690171A1 (ru) 2016-06-30
IL243011A0 (en) 2016-03-31
IN2013MU02285A (enExample) 2015-06-19
NZ715246A (en) 2017-07-28
CN105431454A (zh) 2016-03-23
WO2015004679A1 (en) 2015-01-15
SG11201510342VA (en) 2016-01-28
US20160215319A1 (en) 2016-07-28
TW201514305A (zh) 2015-04-16
AU2014288811A1 (en) 2016-01-28
BR112015032800A2 (pt) 2017-07-25
EP3019528A1 (en) 2016-05-18
AR096839A1 (es) 2016-02-03

Similar Documents

Publication Publication Date Title
AU2014288811B2 (en) Improved process for production of monoclonal antibodies
JP6982578B2 (ja) 細胞培養培地
KR102301702B1 (ko) 재조합 단백질의 갈락토오스 함량을 증가시키는 방법
JP2021107459A (ja) タンパク質産物の等電性プロファイルをシフトさせる方法およびその使用
JP6674028B2 (ja) モノクローナル抗体組成物中のアフコシル化種の調節
HK1208496A1 (en) Cell culture compositions and methods for polypeptide production
JP7267284B2 (ja) ポリエーテルイオノフォアを使用するタンパク質マンノシル化プロファイルの調節方法
EP3455363B1 (en) Methods for modulating protein galactosylation profiles of recombinant proteins using peracetyl galactose
EP3400242A1 (en) Reduction of high molecular weight species, acidic charge species, and fragments in a monoclonal antibody composition
US20180320128A1 (en) Methods for modulating production profiles of recombinant proteins
WO2016153041A1 (ja) 銅イオン制御製造方法
JP6108170B2 (ja) 細胞培養用培地
JP2018531619A (ja) 灌流様式において組換えたんぱく質の生産プロファイルを調節する方法
US10526631B1 (en) Method of reducing serine for asparagine misincorporation
KR20160025622A (ko) 단일클론항체의 생산에 대한 개선된 공정
US11186858B1 (en) Methods for increasing biosimilarity
JP7051820B2 (ja) 組換えタンパク質の生産プロファイルを改変するための方法
US20240425894A1 (en) Cell culture processes
CN118516439A (zh) 一种提高IgG2B型二硫键异构体比例的方法
WO2025120067A1 (en) Cell culture processes
WO2016162514A1 (en) Methods for modulating protein glycosylation profiles of recombinant proteins
HK1224337A1 (zh) 使用含高浓度氨基酸的培养基的细胞培养方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160106

FZDE Discontinued

Effective date: 20190508